ARTICLE | Company News
CancerVax other research news
September 6, 2004 7:00 AM UTC
Researchers published in FASEB that an 11-nucleotide T-oligo reduced tumor growth by 85-90% in a mouse model of melanoma. CNVX licensed the technology from SemaCo Inc. (Boston, Mass.) (see BioCentury,...